Large-scale pancreatic cancer detection via non-contrast CT and deep learning

Kai Cao(Shanghai Institute of Hematology), Yingda Xia(Alibaba Group (United States)), Jiawen Yao(Zhejiang Lab), Xu Han(First Affiliated Hospital Zhejiang University), Lukáš Lambert(Charles University), Tingting Zhang(Shanghai Jiao Tong University), Wei Tang(Fudan University Shanghai Cancer Center), Gang Jin, Hui Jiang, Xu Fang(Shanghai Institute of Hematology), Isabella Nogues(Harvard University), Xuezhou Li(Shanghai Institute of Hematology), Wenchao Guo(Zhejiang Lab), Yu Wang(Zhejiang Lab), Wei Fang(Zhejiang Lab), Mingyan Qiu(Zhejiang Lab), Yang Hou(China Medical University), Tomáš Kovárník(Charles University), Michal Vočka(Charles University), Yimei Lu(Fudan University Shanghai Cancer Center), Yingli Chen, Xin Chen(Guangdong Provincial People's Hospital), Zaiyi Liu(Guangdong Provincial People's Hospital), Jian Zhou(Sun Yat-sen University), Chuanmiao Xie(Sun Yat-sen University), Rong Zhang(Sun Yat-sen University), Hong Lu(Tianjin Medical University Cancer Institute and Hospital), Gregory D. Hager(Johns Hopkins University), Alan Yuille(Johns Hopkins University), Le Lü(Alibaba Group (United States)), Chengwei Shao(Shanghai Institute of Hematology), Yu Shi(China Medical University), Qi Zhang(First Affiliated Hospital Zhejiang University), Tingbo Liang(First Affiliated Hospital Zhejiang University), Ling Zhang(Alibaba Group (Cayman Islands)), Jianping Lu(Tongji University)
Nature Medicine
November 20, 2023
Cited by 295Open Access
Full Text

Abstract

Pancreatic ductal adenocarcinoma (PDAC), the most deadly solid malignancy, is typically detected late and at an inoperable stage. Early or incidental detection is associated with prolonged survival, but screening asymptomatic individuals for PDAC using a single test remains unfeasible due to the low prevalence and potential harms of false positives. Non-contrast computed tomography (CT), routinely performed for clinical indications, offers the potential for large-scale screening, however, identification of PDAC using non-contrast CT has long been considered impossible. Here, we develop a deep learning approach, pancreatic cancer detection with artificial intelligence (PANDA), that can detect and classify pancreatic lesions with high accuracy via non-contrast CT. PANDA is trained on a dataset of 3,208 patients from a single center. PANDA achieves an area under the receiver operating characteristic curve (AUC) of 0.986-0.996 for lesion detection in a multicenter validation involving 6,239 patients across 10 centers, outperforms the mean radiologist performance by 34.1% in sensitivity and 6.3% in specificity for PDAC identification, and achieves a sensitivity of 92.9% and specificity of 99.9% for lesion detection in a real-world multi-scenario validation consisting of 20,530 consecutive patients. Notably, PANDA utilized with non-contrast CT shows non-inferiority to radiology reports (using contrast-enhanced CT) in the differentiation of common pancreatic lesion subtypes. PANDA could potentially serve as a new tool for large-scale pancreatic cancer screening.


Related Papers

No related papers found

Powered by citation graph analysis